It's too early to tell. What I'd say is that, let me just kind of give a broader - we expected this question with respect to the coronavirus. It's certainly an evolving topic, one that we're watching really closely. So to kind of put into the three buckets, starting first with colleagues, we have a Hong Kong office that has reopened after the extended Lunar New Year. We will put all the processes in place, really the protocol that we developed under the SARS epidemic to - with the coronavirus to protect our workers, make sure we've got flexible schedules. So we are in good stead for now with our colleagues. With respect Omar to your question about customers, you know, so Macy's, the Bloomingdale's, we have about 70 stores that have a strong Asian customer base, so that’s either local, like a store like Flushing or tourist based which would be a store like Union Square. And we've seen some slowdown of sales in these stores this month, nothing to be concerned about yet. But we believe that this - you know, that this is unfolding, so we will see how that goes. And then the third bucket is really the product piece, which is what's going on with our supply chain. We expect a slowdown. We have seen a slowdown, a product that's flowing out of China, nothing concerning yet. And we're watching this one very, very carefully. You know, this is an example of where the tariff situation actually over the last 18 months really gave us a very clear line of sight into our product flow from China for both our national and our private brands. So for our private brands, we're working really closely with our suppliers there. Our team that is in Hong Kong is working with all of our suppliers. We've got - those teams that have come back after Lunar Year. We know exactly what the production of factories are, goods that have been finished goods that are in process, fabric that's been allocated to current and future deliveries. So we're looking at all of that. We're managing that receipt flow. And for international brands, we’re working with our partners very closely on the impact and product availability. So that's all factored right now, but we're watching this. It's an evolving situation. And as Paula mentioned in her remarks, any effectiveness in our sales and earnings has not been factored in our 2020 guidance.